WallStreetZenWallStreetZen

NASDAQ: AZN
ASTRAZENECA PLC Stock Forecast, Predictions & Price Target

Analyst price target for AZN

Based on 1 analyst offering 12 month price targets for ASTRAZENECA PLC.
Min Forecast
$75.00+13.28%
Avg Forecast
$75.00+13.28%
Max Forecast
$75.00+13.28%

Should I buy or sell AZN stock?

Based on 3 analysts offering ratings for ASTRAZENECA PLC.
Hold
Strong Buy
0 analysts 0%
Buy
1 analysts 33.33%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

AZN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
SVB Leerink
Bottom 1%
1
BuyMaintains$75.00+13.28%2022-05-04
DZ Bank
Top 31%
70
HoldUpgradesN/AN/A2022-02-11
Jefferies
Bottom 23%
23
HoldDowngradesN/AN/A2021-12-07

1 of 1

Forecast return on equity

Is AZN forecast to generate an efficient return?
Company
22%
Industry
124.5%
Market
30.97%
AZN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AZN forecast to generate an efficient return on assets?
Company
7.97%
Industry
17.59%
AZN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AZN earnings per share forecast

What is AZN's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$3.34
Avg 2 year Forecast
$3.77
Avg 3 year Forecast
$4.51

AZN revenue forecast

What is AZN's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$44.0B+6.14%
Avg 2 year Forecast
$46.8B+12.85%
Avg 3 year Forecast
$51.4B+23.78%
AZN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AZN revenue growth forecast

How is AZN forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
7.37%
Industry
1.93%
Market
9.18%
AZN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AZN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AZN vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
AZN$66.21$75.00+13.28%Hold
NVS$89.42N/AN/ASell
MRK$93.55$92.50-1.12%Buy
BMY$76.19$72.00-5.50%Hold
ABBV$151.01$166.10+9.99%Buy

ASTRAZENECA Stock Forecast FAQ

Is ASTRAZENECA Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AZN) stock is to Hold AZN stock.

Out of 3 analysts, 0 (0%) are recommending AZN as a Strong Buy, 1 (33.33%) are recommending AZN as a Buy, 2 (66.67%) are recommending AZN as a Hold, 0 (0%) are recommending AZN as a Sell, and 0 (0%) are recommending AZN as a Strong Sell.

What is AZN's earnings growth forecast for 2022-2024?

(NASDAQ: AZN) ASTRAZENECA's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 13.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.77%.

ASTRAZENECA's earnings in 2022 is -$1,063,000,000.On average, 5 Wall Street analysts forecast AZN's earnings for 2022 to be $5,174,998,221, with the lowest AZN earnings forecast at $5,051,046,168, and the highest AZN earnings forecast at $5,236,974,248. On average, 5 Wall Street analysts forecast AZN's earnings for 2023 to be $5,841,240,507, with the lowest AZN earnings forecast at $5,562,348,387, and the highest AZN earnings forecast at $6,228,590,673.

In 2024, AZN is forecast to generate $6,987,796,999 in earnings, with the lowest earnings forecast at $6,925,820,973 and the highest earnings forecast at $7,065,267,032.

What is AZN's revenue growth forecast for 2022-2024?

(NASDAQ: AZN) ASTRAZENECA's forecast annual revenue growth rate of 7.37% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 1.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.18%.

ASTRAZENECA's revenue in 2022 is $41,487,000,000.On average, 3 Wall Street analysts forecast AZN's revenue for 2022 to be $68,224,361,285,974, with the lowest AZN revenue forecast at $67,688,666,851,855, and the highest AZN revenue forecast at $68,689,579,681,445. On average, 3 Wall Street analysts forecast AZN's revenue for 2023 to be $72,541,956,815,278, with the lowest AZN revenue forecast at $71,570,070,457,747, and the highest AZN revenue forecast at $73,467,931,332,305.

In 2024, AZN is forecast to generate $79,563,933,593,098 in revenue, with the lowest revenue forecast at $76,026,425,662,406 and the highest revenue forecast at $83,350,008,773,675.

What is AZN's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: AZN) forecast ROA is 7.97%, which is lower than the forecast US Drug Manufacturers - General industry average of 17.59%.

What is AZN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year AZN price target, the average AZN price target is $75.00, with the highest AZN stock price forecast at $75.00 and the lowest AZN stock price forecast at $75.00.

The Wall Street analyst predicted that ASTRAZENECA's share price could reach $75.00 by May 4, 2023. The average ASTRAZENECA stock price prediction forecasts a potential upside of 13.28% from the current AZN share price of $66.21.

What is AZN's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: AZN) ASTRAZENECA's current Earnings Per Share (EPS) is -$0.43. On average, analysts forecast that AZN's EPS will be $3.34 for 2022, with the lowest EPS forecast at $3.26, and the highest EPS forecast at $3.38. On average, analysts forecast that AZN's EPS will be $3.77 for 2023, with the lowest EPS forecast at $3.59, and the highest EPS forecast at $4.02. In 2024, AZN's EPS is forecast to hit $4.51 (min: $4.47, max: $4.56).

What is AZN's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: AZN) forecast ROE is 22%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.